Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
For patients with HER2-positive early-stage breast cancer, NCCN guidelines recommend chemotherapy plus targeted therapy as the standard adjuvant treatment for patients with tumors larger than 1 cm or lymph node-positive. The APT study enrolled patients with stage I HER2-positive breast cancer and has confirmed the efficacy and safety of intravenous chemotherapy combined with targeted therapy, but only 2.2% of the patients enrolled in microinvasion are enrolled, and there is a lack of large sample size data to provide a treatment reference for these patients. In order to further explore the optimal strategy for adjuvant therapy in this type of patient, we designed a new clinical trial to evaluate the efficacy and safety of oral capecitabine plus pyrotinib as adjuvant therapy in previous retrospective studies.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjentki w wieku 18-70 lat.
- •Rak piersi we wczesnym stadium, po operacji, bez nacieku większego niż 1 mm i bez zajętych węzłów chłonnych.
- •Rak piersi potwierdzony jako HER2-dodatni.
- •Pacjentki, których organizm jest w dobrej kondycji ogólnej.
✗ Disqualifies
- •Rak piersi z naciekiem większym niż 1 mm lub z zajętymi węzłami chłonnymi.
- •Rak piersi HER2-ujemny.
- •Pacjentki, które przed badaniem otrzymywały inne leczenie niż operacja (np. chemioterapię, radioterapię).
- •Pacjentki z historią innych nowotworów w ciągu ostatnich 5 lat (z pewnymi wyjątkami).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Last updated (source)
- March 22, 2024
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Breast cancer institute of Fudan University Cancer Hospital
Shanghai, China
Trial contact
Zhimin Shao, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.